Berry Oncology focuses on advancing cancer early detection and precision treatment through innovative technologies. Their core offerings include cfDNA (cell-free DNA) multi-dimensional whole genome sequencing (WGS) and advanced algorithms for cancer screening. The company has developed a multi-cancer early screening product, 全思宁 TM, which utilizes a single blood sample to detect multiple high-risk cancers prevalent in China, such as liver and lung cancer. This product has demonstrated impressive sensitivity and specificity rates, making it a leader in the field of cancer early detection. Additionally, Berry Oncology has established a robust research foundation, conducting large-scale prospective studies to validate their screening technologies, which have been published in reputable international journals.

The company also emphasizes the importance of integrating advanced molecular testing throughout the cancer care continuum, from genetic susceptibility assessments to early screening and treatment monitoring. Their liver cancer early screening product, 莱思宁 ®, leverages comprehensive genomic analysis to identify significant variations in cfDNA, enabling earlier detection of liver cancer. This product has been recognized in the first "Expert Consensus on Early Screening Strategies for Liver Cancer in China," highlighting its clinical relevance and effectiveness. Berry Oncology's commitment to innovation is further underscored by their dual CAP certifications and various international quality management certifications, ensuring that their technologies meet high standards of accuracy and reliability in cancer diagnostics.

China

Berry Oncology, founded in 2017 as a member company of Berry Genomics, focuses on genomic testing of cancers.

Berry Oncology

Company Details